Vital Therapies, Inc. (NASDAQ:VTL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday.

According to Zacks, “Vital Therapies, Inc. is a biotherapeutic company. It is focused on developing a cell-based therapy targeting the treatment of acute liver failure. The Company operates in the United States, Europe, and China. Vital Therapies, Inc. is based in San Diego, California. “

Shares of Vital Therapies (NASDAQ:VTL) traded up 5.22% during trading on Thursday, hitting $6.05. 127,883 shares of the stock were exchanged. Vital Therapies has a 12-month low of $2.25 and a 12-month high of $6.58. The stock’s market cap is $255.35 million. The stock has a 50-day moving average of $3.90 and a 200 day moving average of $3.41.

Vital Therapies (NASDAQ:VTL) last posted its quarterly earnings data on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.01. During the same quarter last year, the company posted ($0.30) earnings per share. Equities analysts predict that Vital Therapies will post ($1.31) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Vital Therapies, Inc. (VTL) Stock Rating Lowered by Zacks Investment Research” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/05/vital-therapies-inc-vtl-stock-rating-lowered-by-zacks-investment-research.html.

In other Vital Therapies news, Director Muneer A. Satter purchased 130,000 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were purchased at an average cost of $4.01 per share, for a total transaction of $521,300.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime purchased 10,000 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was acquired at an average price of $4.00 per share, for a total transaction of $40,000.00. Following the completion of the transaction, the director now owns 65,119 shares of the company’s stock, valued at approximately $260,476. The disclosure for this purchase can be found here. Insiders purchased 190,000 shares of company stock valued at $737,800 in the last ninety days. Corporate insiders own 32.60% of the company’s stock.

A number of institutional investors have recently modified their holdings of the business. Susquehanna International Group LLP bought a new stake in Vital Therapies in the second quarter worth about $268,000. Goldman Sachs Group Inc. raised its position in Vital Therapies by 261.4% in the second quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock worth $676,000 after acquiring an additional 168,705 shares in the last quarter. Victory Capital Management Inc. raised its position in Vital Therapies by 1.2% in the second quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock worth $7,480,000 after acquiring an additional 29,840 shares in the last quarter. Blair William & Co. IL raised its position in Vital Therapies by 67.2% in the second quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock worth $289,000 after acquiring an additional 40,000 shares in the last quarter. Finally, LMR Partners LLP bought a new stake in Vital Therapies in the second quarter worth about $396,000. Hedge funds and other institutional investors own 25.58% of the company’s stock.

About Vital Therapies

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Get a free copy of the Zacks research report on Vital Therapies (VTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.